<DOC>
	<DOC>NCT00396227</DOC>
	<brief_summary>This study is designed to evaluate, in a primary care setting, the safety and efficacy of vildaglipgtin as add on therapy to metformin relative to TZD added to metformin in patients with type 2 diabetes inadequately controlled by metformin alone.</brief_summary>
	<brief_title>Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients who have received a stable dose of metformin consisting of at least 1,000 mg/day for four weeks prior to Visit 1 (week2) Agreement to maintain the same dose of metformin from screening to the end of the study Age in the range of 1880 years Body mass index (BMI) in the range of 2240 kg/m2 HbA1c in the range of 7.0 to 10% FPG &lt;270 mg/dL (15 mmol/L) A history of type 1 diabetes Liver disease Treatment with insulin or any oral antidiabetic other than metformin, within 8 weeks prior to Visit 1 Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>hemoglobin A1c</keyword>
	<keyword>metformin</keyword>
</DOC>